World’s most advanced dengue vaccine candidate shows promise in phase 3 trial

11 julio 2014

The first dengue vaccine candidate to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research. There is no licensed vaccine available to treat or prevent dengue fever, and efforts to develop one have been complicated by the fact that dengue is caused by four distinct dengue viruses, and a vaccine must target all four serotypes.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/cq71gS5swgc/140711092039.htm

Volver